ViroPharma
The 10-second takeaway
For the quarter ended June 30 (Q2), ViroPharma missed estimates on revenue and missed estimates on earnings per share.
Compared to the prior-year quarter, revenue shrank significantly and GAAP earnings per share dropped to a loss.
Margins dropped across the board.
Revenue details
ViroPharma recorded revenue of $94.6 million. The 14 analysts polled by S&P Capital IQ wanted to see revenue of $104.4 million on the same basis. GAAP reported sales were 27% lower than the prior-year quarter's $128.8 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS details
EPS came in at $0.09. The nine earnings estimates compiled by S&P Capital IQ predicted $0.18 per share. GAAP EPS were -$0.06 for Q2 against $0.28 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
Margin details
For the quarter, gross margin was 73.9%, 960 basis points worse than the prior-year quarter. Operating margin was 2.9%, 3,160 basis points worse than the prior-year quarter. Net margin was -4.4%, 2,210 basis points worse than the prior-year quarter.
Looking ahead
Next quarter's average estimate for revenue is $104.0 million. On the bottom line, the average EPS estimate is $0.17.
Next year's average estimate for revenue is $449.0 million. The average EPS estimate is $0.94.
Investor sentiment
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 1,205 members out of 1,244 rating the stock outperform, and 39 members rating it underperform. Among 302 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 293 give ViroPharma a green thumbs-up, and nine give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on ViroPharma is hold, with an average price target of $25.40.
- Add ViroPharma to My Watchlist.
